CA2465693A1 - Compositions pharmaceutiques d'atorvastatine - Google Patents
Compositions pharmaceutiques d'atorvastatine Download PDFInfo
- Publication number
- CA2465693A1 CA2465693A1 CA002465693A CA2465693A CA2465693A1 CA 2465693 A1 CA2465693 A1 CA 2465693A1 CA 002465693 A CA002465693 A CA 002465693A CA 2465693 A CA2465693 A CA 2465693A CA 2465693 A1 CA2465693 A1 CA 2465693A1
- Authority
- CA
- Canada
- Prior art keywords
- atorvastatin
- prepared
- unit dosage
- compacts
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47791703P | 2003-06-12 | 2003-06-12 | |
US60/477,917 | 2003-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2465693A1 true CA2465693A1 (fr) | 2004-12-12 |
Family
ID=33551780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002465693A Abandoned CA2465693A1 (fr) | 2003-06-12 | 2004-04-29 | Compositions pharmaceutiques d'atorvastatine |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1635788A1 (fr) |
JP (1) | JP2006527259A (fr) |
KR (1) | KR100760112B1 (fr) |
CN (1) | CN1805732A (fr) |
AR (1) | AR044660A1 (fr) |
AU (1) | AU2004246867A1 (fr) |
BR (1) | BRPI0411354A (fr) |
CA (1) | CA2465693A1 (fr) |
CO (1) | CO5640071A2 (fr) |
MX (1) | MXPA05012955A (fr) |
NO (1) | NO20060149L (fr) |
RU (1) | RU2325903C2 (fr) |
TW (1) | TW200503689A (fr) |
WO (1) | WO2004110406A1 (fr) |
ZA (1) | ZA200508204B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007004425A (es) * | 2004-10-18 | 2007-06-07 | Teva Pharma | Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente. |
CA2547216A1 (fr) * | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Procede de recuit de l'atorvastatine amorphe |
KR101381076B1 (ko) | 2006-03-29 | 2014-04-02 | 코와 가부시키가이샤 | 트리글리세리드 저하제 및 고인슐린 혈증 개선제 |
CN101973922B (zh) * | 2009-05-27 | 2013-01-23 | 天津和美生物技术有限公司 | 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用 |
WO2011074961A1 (fr) | 2009-12-18 | 2011-06-23 | Frieslandcampina Nederland Holding B.V. | Composition d'excipient de comprimé co-traité, sa préparation et son utilisation |
SG181787A1 (en) * | 2009-12-22 | 2012-07-30 | Novartis Ag | Formulation comprising 1 h - quinazoline - 2, 4 - dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof |
EP2575757A1 (fr) | 2010-06-03 | 2013-04-10 | Mahmut Bilgic | Formulation hydrosoluble stable |
EA018867B1 (ru) * | 2012-11-01 | 2013-11-29 | Лаборатория Тютор С.А.С.И.Ф.И.А. | Способ получения фармацевтической композиции и продукт способа |
CN104825449A (zh) * | 2014-02-12 | 2015-08-12 | 天津药物研究院 | 含有阿托伐他汀钙和氨氯地平的复方组合物及其制备方法 |
JP6306690B2 (ja) * | 2014-09-26 | 2018-04-04 | 株式会社フジクラ | 光ファイバ |
RU2591079C2 (ru) * | 2014-12-10 | 2016-07-10 | Александр Владимирович Диковский | Фармацевтическая композиция статинов с пребиотиком для терапии гиперхолестеринемии и гиперлипидимии |
AU2016274442B2 (en) * | 2015-06-10 | 2021-08-05 | Evonik Operations Gmbh | Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer |
US20180303799A1 (en) * | 2015-10-16 | 2018-10-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd | An Oral Preparation for the Treatment of Cardiovascular Disease and Its Preparation Method |
WO2023025672A1 (fr) | 2021-08-25 | 2023-03-02 | Basf Se | Composition auxiliaire de compression directe |
CN114674944A (zh) * | 2022-03-04 | 2022-06-28 | 苏州东瑞制药有限公司 | 一种检测苯磺酸氨氯地平与阿托伐他汀钙复方制剂有关物质的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2349364T3 (es) * | 1999-11-17 | 2010-12-30 | Teva Pharmaceutical Industries, Ltd. | Procedimiento para la preparación de una forma polimórfica de atorvastatina cálcica. |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
PL369268A1 (en) * | 2001-03-27 | 2005-04-18 | Ranbaxy Laboratories Limited | A stable pharmaceutical composition of pravastatin |
JP2003055217A (ja) * | 2001-08-10 | 2003-02-26 | Taiyo Yakuhin Kogyo Kk | 医薬組成物 |
GB0121436D0 (en) * | 2001-09-04 | 2001-10-24 | Pfizer Ltd | Biomodulated multiparticulate formulations |
CA2385529A1 (fr) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Formulations posologiques stables contenant de l'atorvastatin calcium |
WO2004056358A1 (fr) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Formes posologiques comprenant un inhibiteur de cetp et un inhibiteur de hmg-coa reductase |
-
2004
- 2004-04-29 CA CA002465693A patent/CA2465693A1/fr not_active Abandoned
- 2004-06-01 EP EP04735617A patent/EP1635788A1/fr not_active Withdrawn
- 2004-06-01 RU RU2005136743/15A patent/RU2325903C2/ru not_active IP Right Cessation
- 2004-06-01 CN CNA200480016386XA patent/CN1805732A/zh active Pending
- 2004-06-01 JP JP2006516511A patent/JP2006527259A/ja active Pending
- 2004-06-01 WO PCT/IB2004/001859 patent/WO2004110406A1/fr active Application Filing
- 2004-06-01 MX MXPA05012955A patent/MXPA05012955A/es unknown
- 2004-06-01 AU AU2004246867A patent/AU2004246867A1/en not_active Abandoned
- 2004-06-01 KR KR1020057023718A patent/KR100760112B1/ko not_active IP Right Cessation
- 2004-06-01 BR BRPI0411354-3A patent/BRPI0411354A/pt not_active IP Right Cessation
- 2004-06-09 TW TW093116574A patent/TW200503689A/zh unknown
- 2004-06-10 AR ARP040102009A patent/AR044660A1/es unknown
-
2005
- 2005-10-11 ZA ZA200508204A patent/ZA200508204B/xx unknown
- 2005-12-07 CO CO05124314A patent/CO5640071A2/es unknown
-
2006
- 2006-01-10 NO NO20060149A patent/NO20060149L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CO5640071A2 (es) | 2006-05-31 |
JP2006527259A (ja) | 2006-11-30 |
AR044660A1 (es) | 2005-09-21 |
MXPA05012955A (es) | 2006-02-13 |
AU2004246867A1 (en) | 2004-12-23 |
NO20060149L (no) | 2006-03-06 |
KR100760112B1 (ko) | 2007-09-18 |
RU2005136743A (ru) | 2006-07-27 |
WO2004110406A1 (fr) | 2004-12-23 |
EP1635788A1 (fr) | 2006-03-22 |
TW200503689A (en) | 2005-02-01 |
KR20060025167A (ko) | 2006-03-20 |
RU2325903C2 (ru) | 2008-06-10 |
CN1805732A (zh) | 2006-07-19 |
ZA200508204B (en) | 2007-03-28 |
BRPI0411354A (pt) | 2006-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090196932A1 (en) | Pharmaceutical compositions of atorvastatin | |
US20090226510A1 (en) | Pharmaceutical compositions of atorvastatin | |
US7790197B2 (en) | Pharmaceutical compositions of atorvastatin | |
EP1849459A1 (fr) | Compositions d'ézétimibe | |
KR100674762B1 (ko) | 암로디핀 및 아토르바스타틴의 약학 조성물 | |
KR100760112B1 (ko) | 아토르바스타틴의 제약 조성물 | |
CA2582405A1 (fr) | Compositions pharmaceutiques contenant du fenofibrate et de l'atorvastatine | |
AU2004246868B2 (en) | Stable compositions of atorvastatin prepared with wet granulation | |
EP2364138A2 (fr) | Formulation de palonosétron | |
WO2013072770A2 (fr) | Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride | |
AU2008200759A1 (en) | Stable compositions of atorvastatin prepared with wet granulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |